These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 38685282)

  • 1. Targeting focal adhesion kinase (FAK) for cancer therapy: FAK inhibitors, FAK-based dual-target inhibitors and PROTAC degraders.
    Yang M; Xiang H; Luo G
    Biochem Pharmacol; 2024 Jun; 224():116246. PubMed ID: 38685282
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting focal adhesion kinase (FAK) in cancer therapy: A recent update on inhibitors and PROTAC degraders.
    Wang X; Li N; Liu YH; Wu J; Liu QG; Niu JB; Xu Y; Huang CZ; Zhang SY; Song J
    Eur J Med Chem; 2024 Oct; 276():116678. PubMed ID: 39029337
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug Discovery Targeting Focal Adhesion Kinase (FAK) as a Promising Cancer Therapy.
    Pang XJ; Liu XJ; Liu Y; Liu WB; Li YR; Yu GX; Tian XY; Zhang YB; Song J; Jin CY; Zhang SY
    Molecules; 2021 Jul; 26(14):. PubMed ID: 34299525
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progress in the Development of Small Molecular Inhibitors of Focal Adhesion Kinase (FAK).
    Lu Y; Sun H
    J Med Chem; 2020 Dec; 63(23):14382-14403. PubMed ID: 33058670
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development and Characterization of Selective FAK Inhibitors and PROTACs with In Vivo Activity.
    Koide E; Mohardt ML; Doctor ZM; Yang A; Hao M; Donovan KA; Kuismi CC; Nelson AJ; Abell K; Aguiar M; Che J; Stokes MP; Zhang T; Aguirre AJ; Fischer ES; Gray NS; Jiang B; Nabet B
    Chembiochem; 2023 Oct; 24(19):e202300141. PubMed ID: 37088717
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Focal adhesion kinase as a cancer therapy target.
    Golubovskaya VM
    Anticancer Agents Med Chem; 2010 Dec; 10(10):735-41. PubMed ID: 21214510
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FAK inhibitors in cancer, a patent review - an update on progress.
    Ye YX; Cao YY; Xu LS; Wang HC; Liu XH; Zhu HL
    Expert Opin Ther Pat; 2024 Aug; 34(8):593-610. PubMed ID: 38946486
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oncogenic Receptor Tyrosine Kinases Directly Phosphorylate Focal Adhesion Kinase (FAK) as a Resistance Mechanism to FAK-Kinase Inhibitors.
    Marlowe TA; Lenzo FL; Figel SA; Grapes AT; Cance WG
    Mol Cancer Ther; 2016 Dec; 15(12):3028-3039. PubMed ID: 27638858
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of novel and potent PROTACs targeting FAK for non-small cell lung cancer: Design, synthesis, and biological study.
    Sun Y; Wang R; Sun Y; Wang L; Xue Y; Wang J; Wu T; Yin W; Qin Q; Sun Y; Zhao D; Cheng M
    Eur J Med Chem; 2022 Jul; 237():114373. PubMed ID: 35486993
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FAK inhibitors in Cancer, a patent review.
    Lv PC; Jiang AQ; Zhang WM; Zhu HL
    Expert Opin Ther Pat; 2018 Feb; 28(2):139-145. PubMed ID: 29210300
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Focal adhesion kinase-An emerging viable target in cancer and development of focal adhesion kinase inhibitors.
    Chauhan A; Khan T
    Chem Biol Drug Des; 2021 Mar; 97(3):774-794. PubMed ID: 33191630
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Focal adhesion kinase inhibitors in the treatment of metastatic cancer: a patent review.
    Shanthi E; Krishna MH; Arunesh GM; Venkateswara Reddy K; Sooriya Kumar J; Viswanadhan VN
    Expert Opin Ther Pat; 2014 Oct; 24(10):1077-100. PubMed ID: 25113248
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent Advances of Small Molecule Focal Adhesion Kinase (FAK) Inhibitors as Promising Anticancer Therapeutics.
    Lv P; Chen K; Zhu HL
    Curr Med Chem; 2021 Oct; 28(34):6977-6989. PubMed ID: 33797359
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FAK signaling in human cancer as a target for therapeutics.
    Lee BY; Timpson P; Horvath LG; Daly RJ
    Pharmacol Ther; 2015 Feb; 146():132-49. PubMed ID: 25316657
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Focal adhesion kinase: a potential target in cancer therapy.
    van Nimwegen MJ; van de Water B
    Biochem Pharmacol; 2007 Mar; 73(5):597-609. PubMed ID: 16997283
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of focal adhesion kinase inhibitors in cancer therapy.
    Ma WW
    Anticancer Agents Med Chem; 2011 Sep; 11(7):638-42. PubMed ID: 21787276
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FAK inhibitors as promising anticancer targets: present and future directions.
    Mustafa M; Abd El-Hafeez AA; Abdelhafeez DA; Abdelhamid D; Mostafa YA; Ghosh P; Hayallah AM; A Abuo-Rahma GE
    Future Med Chem; 2021 Sep; 13(18):1559-1590. PubMed ID: 34340532
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Development of FAK Inhibitors: A Five-Year Update.
    Spallarossa A; Tasso B; Russo E; Villa C; Brullo C
    Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35742823
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting FAK in anticancer combination therapies.
    Dawson JC; Serrels A; Stupack DG; Schlaepfer DD; Frame MC
    Nat Rev Cancer; 2021 May; 21(5):313-324. PubMed ID: 33731845
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Addressing Kinase-Independent Functions of Fak via PROTAC-Mediated Degradation.
    Cromm PM; Samarasinghe KTG; Hines J; Crews CM
    J Am Chem Soc; 2018 Dec; 140(49):17019-17026. PubMed ID: 30444612
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.